First test of new prostate cancer pill in china
NCT ID NCT06136598
Summary
This early-stage study tested a new oral drug called MK-5684 (opevesostat) in 14 Chinese men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The main goals were to check the drug's safety, see how well it was tolerated, and measure how the body processes it. Researchers also looked for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University First Hospital-Urology ( Site 0001)
Beijing, Beijing Municipality, 100034, China
-
Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003)
Guangzhou, Guangdong, 510700, China
-
Tongji Hospital Tongji Medical,Science & Technology ( Site 0002)
Wuhan, Hubei, 430000, China
Conditions
Explore the condition pages connected to this study.